Send PM
Followers 13
Posts 93
Boards Moderated 0
Alias Born 07/13/2022

Re: None

Thursday, 11/17/2022 7:19:07 PM

Thursday, November 17, 2022 7:19:07 PM

Post# of 540037
I just watched Dr. Steven Brem of UPenn give a preview and highlights of Dr. Liau's presentation on Sunday. He gave it during a CME symposium timed to coincide with SNO. He was careful to give Dr. Liau lots of credit, but you could also tell he was incredibly proud of the data and the positive results. He joked about his poor batting average, having been involved in about 100 of the roughly 400 previous failed clinical trials in GBM. He presented one main slide, with lots of condensed highlights on it, all text and no graphics or Kaplan Meier curves as I recall, I think he was trying to avoid stealing Dr. Liau's thunder, but also trying to give his audience some juicy tidbits that would encourage them to watch the full presentation on Sunday. In fact that's exactly what he encouraged his listeners to do.

His presentation was made more powerful by the fact that his predecessor on the podium had just given a long, sad recap of many failed efforts to advance the SOC in GBM, including a wide variety of therapies such as bevacizumab, rindopepimut, nivolumab, pembrolizumab, etc. etc. The gentleman who spoke before Dr. Brem had an Indian name I will not try to spell here, but he said he was excited about the prospects of a targeted therapy against the NTRK gene fusion, he mentioned two competing therapies one is larotrectinib, the other entrectinib (the former made by Bayer, the latter made by Genentech), and he showed promising clinical trial data. But he also mentioned that the NTRK gene fusion is only found in a very small percentage of patients with GBM, I think he said 1% or maybe 4%. In any case, it's only a tiny fraction of the total population. It's clear that to me that the dendritic cell vaccine approach is vastly superior, since by using the patient's own tumor antigens, the whole problem of antigen targeting is solved in the most effective possible way.

Morale is high tonight.

Go team NWBO!

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Recent NWBO News

FEATURED Goldshore Intersects Additional High-Grade Shears in the QES Zone at the Moss Lake Gold Project Nov 28, 2022 8:39 AM


Branded Legacy, Inc. Signs Joint Venture To Add Additional $300,000 a Year In Revenue BLEG Nov 23, 2022 11:10 AM

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial CMND Nov 23, 2022 9:50 AM

Branded Legacy, Inc. Gets Approval From State to Reduce Authorized Common Shares by 300 Million BLEG Nov 22, 2022 1:15 PM

Defiance Resumes Drilling In Zacatecas DNCVF Nov 22, 2022 11:53 AM

InnerScope Hearing Technologies (OTC: INND) Announces its HearingAssist Brand of OTC Hearing Aids on INND Nov 22, 2022 11:52 AM

ECRID Offers Federal Housing Finance Agency (FHFA) Credit & Lending Platform to Immediately Assist Low-Credit and No-Credit Home Buyers, and Others ECDD Nov 22, 2022 11:51 AM

BioLife Sciences Inc. (OTC:PK BLFE) is Pleased to Announce Its Q1 2023 Slated Release of Its Copper-Infused Fabric Pot Prototype BLFE Nov 22, 2022 11:50 AM

Fission 3.0 Hits Off-Scale Radioactivity in New Discovery on PLN A1 Conductor FUU Nov 21, 2022 11:05 AM

Perpetual Industries Reports Strong Third-Quarter PRPI Nov 21, 2022 8:00 AM

Nextech AR Solutions Corp. Reports Record Q3 Sequential Growth As 3D Modeling Revenue Surges +192% and Gross Profit Margin Improves To +60% NEXCF Nov 17, 2022 7:03 PM

AgriFORCE Receives Notice of Allowance Related to its FORCEGH+ Facility from the United States Patent and Trademark Office AGRIW Nov 17, 2022 9:06 AM

Organicell Starts Enrolling Long COVID Trial OCEL Nov 17, 2022 8:38 AM

Mullen Announces Funding to Close on ELMS Assets MULN Nov 17, 2022 8:30 AM